Safety by Design for Cytotoxic Tabletting
Gamlen Tableting will be launching the GTP-SafeTab at AAPS 2014. The GTP-SafeTab incorporates an innovative containment solution to enable the use of a Gamlen Tablet Press with cytotoxic and other highly-potent APIs.
With space to enable the operator to use a Gamlen Tablet Press along with other equipment, the GTP-SafeTab system is a completely self-contained environment designed precisely for cytotoxic work.
Michael Gamlen, Managing Director, explains: "When handling biologically reactive materials you must protect the operator. Normally you would use a fume cupboard or a biological cabinet. Gamlen Tableting has developed a HEPA filtered semi-disposable cabinet system that can be used anywhere, providing a flexible and economical alternative to retrofitting containment solutions on existing equipment.
The Gamlen Tablet Press is ideal for cytotoxic work as it has few components and crevices to entrap material and allows early analysis and assessment of material properties using tiny amounts of material to reduce waste, save time and money.
The GTP-SafeTab will be launched at AAPS 2014 in San Diego, 2-6 November at booth #3612. Entirely computer controlled, the GTP is a portable laboratory machine that can be used to discover more about tablets and tableting conditions including: compaction, compression, ejection force, hardness, lubricity, tensile fracture stress and humidity effects.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...